Toronto, ON – September 25, 2024 — MDBriefCase, a leading provider of interactive accredited continuing medical education for healthcare professionals, is proud to announce the upcoming relaunch of RxBriefCase in partnership with Pharmapod, the top medication safety reporting platform for pharmacists.
Launching in early 2025, RxBriefCase will offer a comprehensive range of accredited on-demand pharmacy courses designed to keep pharmacists’ skills sharp and current in an evolving healthcare landscape.
RxBriefCase courses will cover a diverse array of topics, including patient safety, travel medicine, medication management, and infectious disease, ensuring that pharmacists have access to the latest professional development resources. The platform’s relaunch highlights MDBriefCase’s commitment to excellence in clinical education and support for healthcare professionals.
Sachin Aggarwal, CEO of Think Research, said, “Our goal is to empower pharmacists with the tools and knowledge they need to excel in their roles and provide exceptional patient care. RxBriefCase will serve as a trusted resource for ongoing professional development, helping pharmacists stay informed about the latest advancements in the field.”
Janet Kimura, Managing Director & EVP, Clinical Content and Education at MDBriefCase, added, “We are thrilled to bring RxBriefCase back with enhanced content and features that align with the needs of today’s pharmacists. Our team is dedicated to curating high-quality educational experiences that support pharmacists in their lifelong learning journeys.”
Brynne Eaton-Auva’a, Managing Director, Clinical Connectivity, said, “We’re incredibly proud to relaunch RxBriefCase in partnership with Pharmapod, combining our educational expertise with leadership in patient safety. This collaboration will bring educational resources to Pharmapod users and represents a major step forward in empowering pharmacists with cutting-edge knowledge while supporting the highest standards of care. Our aim is to make pharmacy safety and professional development as accessible, relevant, and impactful as possible for today’s pharmacists.”
Pharmacists can look forward to an engaging, user-friendly platform designed to fit seamlessly into their busy schedules, offering flexibility and convenience in accessing crucial educational resources.
In collaboration with Pharmapod, the leading platform for pharmacy safety, courses will also be accessible directly through Pharmapod, enhancing the user experience by integrating continuing education with quality improvement solutions.
RxBriefCase is scheduled to relaunch in early 2025. Join our mailing list to be notified when the site is live.
For more information, contact Janet Kimura janet.kimura@mdbriefcase.com.
About MDBriefCase
MDBriefCase, a Think Research subsidiary, is a leading provider of accredited, online continuing professional development (CPD) to help healthcare practitioners enhance their professional practice and stay at the forefront of the latest evidence and protocols. Through innovative partnerships, we offer high-quality content, free of charge, to more than 280,000 members in Canada, Australia, Africa and the Middle East. More information at mdbriefcase.com.
About Pharmapod
Pharmapod is the leading cloud-based continuing quality improvement (CQI) solution for driving efficiencies and reducing patient safety incidents in community pharmacies, long-term care, and hospitals. Built by pharmacists for pharmacists, our technology is chosen globally by industry leaders, regulators, academic sites and national healthcare providers, including 70% of pharmacies in Canada, to drive excellence in medication safety and promote data-driven innovation, safety and quality improvements. More information at pharmapodhq.com.
RxBriefCase, MDBriefCase and Pharmapod are members of the Think Research family of companies.
199 Bay Street #4000, Toronto,
ON M5L 1A9
In submitting your work (the “Work”) for potential posting on the MDBriefCase Healthcare Leadership Academy website (the “Website”), you (“You”) expressly agree to the following:
Review: MDBriefCase is pleased to consider the publication of Your Work on the Website. The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.
Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered. If posted, You will be identified as the author of the Work, or co-author if applicable.
Grant of Rights: As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats: (1) the exclusive right of first publication worldwide; (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications. The grant of rights survives termination or expiration of this Agreement.
Warranty: You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work. This warranty survives termination or expiration of this Agreement.
Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Academy website.
The Healthcare Leadership Academy welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished. When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.
Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.
Guest articles for the MDBriefCase Healthcare Leadership Academy may run between 500 and 1000 words.
MDBriefCase reserves the right to accept or reject any submission and the right to condition acceptance upon revision of material to conform to its criteria.
There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal websites, corporate websites and social media platforms.
Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.
